exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274616 RNA Name: hsa-miR-19b-3p RNA Type: miRNA Chromosome: chr13 Starnd: + Coordinate: Start Site(bp): 91351245 End Site(bp): 91351267 External Links: hsa-miR-19b-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BCL7A chr12 122019422 122062044 + UBA1 chrX 47190861 47215128 + RPS23 chr5 82273320 82278396 - ALDH3A2 chr17 19648136 19685760 + MEF2D chr1 156463727 156500779 - TBC1D25 chrX 48539714 48562609 + ANAPC16 chr10 72216000 72235860 + PYGB chr20 25248085 25298012 + CASP2 chr7 143288215 143307696 + TUB chr11 8019244 8106112 + SRSF6 chr20 43457893 43466046 + CAMTA1 chr1 6785454 7769706 + PMPCB chr7 103297435 103329511 + RFX1 chr19 13961530 14007039 - BTBD7 chr14 93237550 93333092 - ZNF397 chr18 35241030 35267133 + F13A1 chr6 6144084 6321013 - DNAJC16 chr1 15526813 15592379 + HOMER1 chr5 79372636 79514134 - REV1 chr2 99400475 99490035 - RAB18 chr10 27504174 27542237 + TBL1X chrX 9463295 9741037 + MTREX chr5 55307989 55425579 + PTPN21 chr14 88465778 88555007 - EIF4A2 chr3 186783205 186789897 + PATL1 chr11 59636716 59669037 - ST3GAL5 chr2 85837120 85905199 - USP14 chr18 158383 214629 + CLDN6 chr16 3014712 3020071 - COPB1 chr11 14443440 14500027 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001454 chr4 154524454 154533552 + hsa_circ_0001186 chr21 35475133 35475818 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001605 chr6 42903447 42905047 + hsa_circ_0000155 chr1 168007608 168014465 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000943 chr19 47421744 47440665 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC010997.3 chr10 75279726 75401246 - AC011498.2 chr19 4447304 4448217 + AC011503.2 chr19 23927788 23929287 + AC021078.1 chr5 149494314 149504670 - AC135050.6 chr16 31122235 31124064 + AL049840.4 chr14 103694516 103695050 - AL158206.1 chr9 19453209 19455173 + AL158825.2 chr9 75009828 75016036 - H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - LAMTOR5-AS1 chr1 110347116 110443817 + LINC00667 chr18 5237826 5290608 + MCM3AP-AS1 chr21 46229196 46259390 + NEAT1 chr11 65422774 65445540 + SNHG20 chr17 77086716 77099902 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.